Role of nitric oxide synthase inhibitor in experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid in rats

Tsutomu Hosoi, Hidemi Goto, Tomiyasu Arisawa, Yasumasa Niwa, Naoaki Okada, Naoki Omiya, Tetsuo Hayakawa

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

1. The present study was designed to investigate the role of nitric oxide (NO) in modulating 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. 2. Damage scores and NO synthase (NOS) activity were measured. 3. The damage scores and NOS activity reached a peak on the 4th day after administration of TNBS solution (day 0), thereafter gradually decreasing, and were significantly higher than in the group treated with saline throughout the experimental period. 4. Subsequently, we divided the stage of colitis into two groups, one from day 0 to day 3 after induction of colitis, and the other from day 4 onwards. We evaluated the effects of the NOS inhibitor NGmonomethyl-L-arginine (L-NMMA), on TNBS-hapten-induced colitis and colonic mucosal blood flow. Two different methods of L-NMMA administration, from day 0 to day 3, and from day 4 onwards, were undertaken. 5. The damage score in the early L-NMMA treatment group was significantly higher than in the group without L-NMMA on day 14. In contrast, the damage score in the late L-NMMA treatment group was not significantly different from the group without L-NMMA. Colonic mucosal blood flow in the early L-NMMA treatment group was not significantly different from that in the late L-NMMA treatment group. 6. These data suggest that NO is important for inhibiting inflammation during the early stages.

Original languageEnglish
Pages (from-to)9-12
Number of pages4
JournalClinical and Experimental Pharmacology and Physiology
Volume28
Issue number1-2
DOIs
Publication statusPublished - 16-01-2001
Externally publishedYes

Fingerprint

omega-N-Methylarginine
Sulfonic Acids
Colitis
Nitric Oxide Synthase
Trinitrobenzenes
Nitric Oxide
sym-trinitrobenzene
Haptens
Arginine
Inflammation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Pharmacology
  • Physiology (medical)

Cite this

Hosoi, Tsutomu ; Goto, Hidemi ; Arisawa, Tomiyasu ; Niwa, Yasumasa ; Okada, Naoaki ; Omiya, Naoki ; Hayakawa, Tetsuo. / Role of nitric oxide synthase inhibitor in experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid in rats. In: Clinical and Experimental Pharmacology and Physiology. 2001 ; Vol. 28, No. 1-2. pp. 9-12.
@article{06122b6f8c41437eb35cee6f98854c37,
title = "Role of nitric oxide synthase inhibitor in experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid in rats",
abstract = "1. The present study was designed to investigate the role of nitric oxide (NO) in modulating 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. 2. Damage scores and NO synthase (NOS) activity were measured. 3. The damage scores and NOS activity reached a peak on the 4th day after administration of TNBS solution (day 0), thereafter gradually decreasing, and were significantly higher than in the group treated with saline throughout the experimental period. 4. Subsequently, we divided the stage of colitis into two groups, one from day 0 to day 3 after induction of colitis, and the other from day 4 onwards. We evaluated the effects of the NOS inhibitor NGmonomethyl-L-arginine (L-NMMA), on TNBS-hapten-induced colitis and colonic mucosal blood flow. Two different methods of L-NMMA administration, from day 0 to day 3, and from day 4 onwards, were undertaken. 5. The damage score in the early L-NMMA treatment group was significantly higher than in the group without L-NMMA on day 14. In contrast, the damage score in the late L-NMMA treatment group was not significantly different from the group without L-NMMA. Colonic mucosal blood flow in the early L-NMMA treatment group was not significantly different from that in the late L-NMMA treatment group. 6. These data suggest that NO is important for inhibiting inflammation during the early stages.",
author = "Tsutomu Hosoi and Hidemi Goto and Tomiyasu Arisawa and Yasumasa Niwa and Naoaki Okada and Naoki Omiya and Tetsuo Hayakawa",
year = "2001",
month = "1",
day = "16",
doi = "10.1046/j.1440-1681.2001.03388.x",
language = "English",
volume = "28",
pages = "9--12",
journal = "Clinical and Experimental Pharmacology and Physiology",
issn = "0305-1870",
publisher = "Wiley-Blackwell",
number = "1-2",

}

Role of nitric oxide synthase inhibitor in experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid in rats. / Hosoi, Tsutomu; Goto, Hidemi; Arisawa, Tomiyasu; Niwa, Yasumasa; Okada, Naoaki; Omiya, Naoki; Hayakawa, Tetsuo.

In: Clinical and Experimental Pharmacology and Physiology, Vol. 28, No. 1-2, 16.01.2001, p. 9-12.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Role of nitric oxide synthase inhibitor in experimental colitis induced by 2,4,6-trinitrobenzene sulphonic acid in rats

AU - Hosoi, Tsutomu

AU - Goto, Hidemi

AU - Arisawa, Tomiyasu

AU - Niwa, Yasumasa

AU - Okada, Naoaki

AU - Omiya, Naoki

AU - Hayakawa, Tetsuo

PY - 2001/1/16

Y1 - 2001/1/16

N2 - 1. The present study was designed to investigate the role of nitric oxide (NO) in modulating 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. 2. Damage scores and NO synthase (NOS) activity were measured. 3. The damage scores and NOS activity reached a peak on the 4th day after administration of TNBS solution (day 0), thereafter gradually decreasing, and were significantly higher than in the group treated with saline throughout the experimental period. 4. Subsequently, we divided the stage of colitis into two groups, one from day 0 to day 3 after induction of colitis, and the other from day 4 onwards. We evaluated the effects of the NOS inhibitor NGmonomethyl-L-arginine (L-NMMA), on TNBS-hapten-induced colitis and colonic mucosal blood flow. Two different methods of L-NMMA administration, from day 0 to day 3, and from day 4 onwards, were undertaken. 5. The damage score in the early L-NMMA treatment group was significantly higher than in the group without L-NMMA on day 14. In contrast, the damage score in the late L-NMMA treatment group was not significantly different from the group without L-NMMA. Colonic mucosal blood flow in the early L-NMMA treatment group was not significantly different from that in the late L-NMMA treatment group. 6. These data suggest that NO is important for inhibiting inflammation during the early stages.

AB - 1. The present study was designed to investigate the role of nitric oxide (NO) in modulating 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis in rats. 2. Damage scores and NO synthase (NOS) activity were measured. 3. The damage scores and NOS activity reached a peak on the 4th day after administration of TNBS solution (day 0), thereafter gradually decreasing, and were significantly higher than in the group treated with saline throughout the experimental period. 4. Subsequently, we divided the stage of colitis into two groups, one from day 0 to day 3 after induction of colitis, and the other from day 4 onwards. We evaluated the effects of the NOS inhibitor NGmonomethyl-L-arginine (L-NMMA), on TNBS-hapten-induced colitis and colonic mucosal blood flow. Two different methods of L-NMMA administration, from day 0 to day 3, and from day 4 onwards, were undertaken. 5. The damage score in the early L-NMMA treatment group was significantly higher than in the group without L-NMMA on day 14. In contrast, the damage score in the late L-NMMA treatment group was not significantly different from the group without L-NMMA. Colonic mucosal blood flow in the early L-NMMA treatment group was not significantly different from that in the late L-NMMA treatment group. 6. These data suggest that NO is important for inhibiting inflammation during the early stages.

UR - http://www.scopus.com/inward/record.url?scp=0035175169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035175169&partnerID=8YFLogxK

U2 - 10.1046/j.1440-1681.2001.03388.x

DO - 10.1046/j.1440-1681.2001.03388.x

M3 - Article

VL - 28

SP - 9

EP - 12

JO - Clinical and Experimental Pharmacology and Physiology

JF - Clinical and Experimental Pharmacology and Physiology

SN - 0305-1870

IS - 1-2

ER -